Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi

被引：13

作者：

Zaja, Francesco ^{[1
,2
]}

Salvi, Flavia ^{[3
]}

Rossi, Maura ^{[4
]}

Sabattini, Elena ^{[5
]}

Evangelista, Andrea ^{[5
]}

Ciccone, Giovannino ^{[6
,7
]}

Angelucci, Emanuele ^{[8
]}

Gaidano, Gianluca ^{[9
]}

Zanni, Manuela ^{[9
]}

Ladetto, Marco ^{[3
]}

Chiappella, Annalisa ^{[10
]}

Vitolo, Umberto ^{[10
]}

Zinzani, Pier Luigi ^{[11
]}

Califano, Catello ^{[12
]}

Tucci, Alessandra ^{[13
,14
]}

Patti, Caterina ^{[15
]}

Pileri, Stefano A. ^{[16
]}

Lenti, Valentina ^{[17
]}

Piccaluga, Pier Paolo ^{[4
]}

Cavallo, Federica ^{[18
]}

Volpetti, Stefano ^{[19
,20
]}

Perali, Giulia ^{[19
,20
]}

Assouline, Sarit ^{[21
]}

Mann, Koren Kathleen ^{[22
]}

Morin, Ryan ^{[23
]}

Alcaide, Miguel ^{[23
]}

Bushell, Kevin ^{[23
]}

Fanin, Renato ^{[1
,2
]}

Levis, Alessandro ^{[17
]}

机构：

[1] Univ Udine, Clin Ematol, DAME, Udine, Italy

[2] Univ Udine, Unita Terapie Cellulari Carlo Melzi, DAME, Udine, Italy

[3] AO SS Antonio & Biagio & C Arrigo, SC Ematol, Alessandria, Italy

[4] Univ Hosp Bologna, Unit Haemolymphopathol, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[5] Univ Hosp Bologna, Dept Hematol & Oncol, Unit Haemolymphopathol, Bologna, Italy

[6] AOU Citta Salute & Sci Torino, Unit Clin Epidemiol, Turin, Italy

[7] CPO Piemonte, Turin, Italy

[8] IRCCS AOU San Martino IST, UOC Ematol, Genoa, Italy

[9] Amedeo Avogadro Univ Eastern Piedmont, Dept Translat Med, Div Hematol, Novara, Italy

[10] AOU Citta Salute & Sci, SC Ematol, Turin, Italy

[11] Univ Bologna, Inst Hematol L&A Seragnoli, Bologna, Italy

[12] Osped Umberto I, UO Med Oncoematol, Nocera Inferiore, Italy

[13] Spedali Civil Brescia, SC Ematol, Brescia, Italy

[14] Spedali Civil Brescia, Dipartimento Oncol Med, Brescia, Italy

[15] Osped V Cervello, UOC Ematol, Palermo, Italy

[16] Milano Univ, Sch Med, European Inst Oncol, Haematopathol Unit, Bologna, Italy

[17] Fdn Italiana Linfomi, Alessandria, Italy

[18] Univ Torino, Azienda Osped Univ Citta Salute & Sci, Turin, Italy

[19] Azienda Sanit Univ Integrata, Clin Ematol, Udine, Italy

[20] Azienda Sanit Univ Integrata, Unita Terapie Cellulari Carlo Melzi, Udine, Italy

[21] McGill Univ, Jewish Gen Hosp, Div Hematol, Montreal, PQ, Canada

[22] McGill Univ, Lady Davis Inst, Jewish Gen Hosp, Montreal, PQ, Canada

[23] Simon Fraser Univ, Dept Mol Biol & Biochem, Sch Comp Sci, Vancouver, BC, Canada

来源：

LEUKEMIA & LYMPHOMA | 2018年 / 59卷 / 12期

关键词：

Diffuse large B-cell lymphoma; panobinostat; relapsed/refractory; genomic; DEACETYLASE INHIBITOR PANOBINOSTAT; HISTONE DEACETYLASES; RITUXIMAB; DISEASE; MULTICENTER; ROMIDEPSIN; MUTATION; LBH589; TRIAL; CHOP;

D O I：

10.1080/10428194.2018.1452208

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We investigated panobinostat 40 mg three times weekly in 35 adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Overall response rate and complete response were 17.1% and 11.4%, respectively. Median progression-free survival (PFS) and overall survival were 2.4 and 7.6 months, respectively. Calculated 12, 24 and 36 months PFS were 26%, 11% and 11%, respectively. Four patients who achieved a sustained CR, continued receiving panobinostat for an overall period of 44, 48, 50, 62 months. Thrombocytopenia grade 3 (5 patients) and 4 (24 patients) represented the main toxic effect, causing dose reduction or treatment suspension in 19 patients. Genomic analysis was unable to identify any relationship between mutations and response; TP53 mutation appeared not to impact the clinical outcome. Overall, panobinostat has a modest activity in R/R DLBCL patients, however it can induce very long lasting responses in some cases. Thrombocytopenia frequently limits the use of this agent.

引用

页码：2904 / 2910

页数：7

共 50 条

[11] The "Elderly Project" by the Fondazione Italiana Linfomi (FIL): a prospective multidimensional assessment of elderly patients with diffuse large B-cell lymphoma
Merli, F.
Tucci, A.
Angrilli, F.
Cavallo, F.
Cabras, G.
Fabbri, A.
Mammi, C.
Chiappella, A.
Gussetti, D.
Zilioli, V.
Arcari, A.
Tani, M.
Balzarotti, M.
Fedina, A.
Marcheselli, L.
Spina, M.
ANNALS OF ONCOLOGY, 2015, 26 : 134 - 134
[12] Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi
Merli, Francesco
Luminari, Stefano
Tucci, Alessandra
Arcari, Annalisa
Rigacci, Luigi
Hawkes, Eliza
Chiattone, Carlos S.
Cavallo, Federica
Cabras, Giuseppina
Alvarez, Isabel
Fabbri, Alberto
Re, Alessandro
Puccini, Benedetta
Barraclough, Allison
Delamain, Marcia Torresan
Ferrero, Simone
Usai, Sara Veronica
Ferrari, Angela
Cencini, Emanuele
Pennese, Elsa
Zilioli, Vittorio Ruggero
Marino, Dario
Balzarotti, Monica
Cox, Maria Christina
Zanni, Manuela
Di Rocco, Alice
Lleshi, Arben
Botto, Barbara
Hohaus, Stefan
Merli, Michele
Sartori, Roberto
Gini, Guido
Nassi, Luca
Musuraca, Gerardo
Tani, Monica
Bottelli, Chiara
Kovalchuk, Sofia
Re, Francesca
Flenghi, Leonardo
Molinari, Annalia
Tarantini, Giuseppe
Chimienti, Emanuela
Marcheselli, Luigi
Mammi, Caterina
Spina, Michele
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (11) : 1214 - +
[13] Brentuximab Vedotin As Single Agent in the Treatment of Relapsed/Refractory CD30 Positive Peripheral T-Cell Lymphoma Patients: A Phase 2 Study of the Fondazione Italiana Linfomi
Stefoni, Vittorio
Corradini, Paolo
Orsucci, Lorella
Volpetti, Stefano
Argnani, Lisa
Dodero, Anna
Pellegrini, Cinzia
Zinzani, Pier Luigi
BLOOD, 2020, 136
[14] The Elderly Project By the Fondazione Italiana Linfomi (FIL): A Prospective Multidimensional Assessment of Elderly Patients with Diffuse Large B-Cell Lymphoma
Merli, Francesco
Luminari, Stefano
Tucci, Alessandra
Cavallo, Federica
Mammi, Caterina
Rigacci, Luigi
Finolezzi, Erica
Cabras, Giuseppina
Fabbri, Alberto
Zilioli, Vittorio Ruggero
Marino, Dario
Chiappella, Annalisa
Balzarotti, Monica
Arcari, Annalisa
Gini, Guido
Salvi, Flavia
Hohaus, Stefan
Tani, Monica
Sartori, Roberto
Cox, Maria Christina
Marcheselli, Luigi
Spina, Michele
BLOOD, 2016, 128 (22)
[15] A phase 2 study of bortezomib in relapsed/refractory diffuse large B-Cell lymphoma (DLBCL).
de Vos, S
Fernando, D
Schenkein, DP
Rosen, PJ
BLOOD, 2005, 106 (11) : 267B - 267B
[16] Carfilzomib, lenalidomide, dexamethasone (KRD) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi
Cavallo, Federica
Clerico, Michele
Lucchini, Elisa
Castiglione, Anna
Re, Alessandro
Zilioli, Vittorio Ruggiero
Visco, Carlo
Tani, Monica
Olivieri, Jacopo
Arcaini, Luca
Fabbri, Alberto
Gaidano, Gianluca
Dodero, Anna
Zaja, Francesco
BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (04) : 1404 - 1410
[17] OUTCOME OF AUTOLOGOUS TRANSPLANT IN "FIT" ELDERLY PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B LYMPHOMA: RESULTS OF THE PROSPECTIVE RECANZ STUDY BY THE "FONDAZIONE ITALIANA LINFOMI
Pagani, C.
Musuraca, G.
Cavallo, F.
Zilioli, V. R.
Zanni, M.
Pelliccia, S.
Mannina, D.
Michieli, M.
Vallisa, D.
Tani, M.
Merli, F.
Re, F.
Marcheselli, L.
Campostrini, G.
Grimaldi, D.
Liardo, E. V.
Re, A.
Cox, M. C.
Rossi, G.
Tucci, A.
HAEMATOLOGICA, 2021, 106 (10) : 70 - 70
[18] Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
Marie Maerevoet
Josee M. Zijlstra
George Follows
Rene-Olivier Casasnovas
J. S. P. Vermaat
Nagesh Kalakonda
Andre Goy
Sylvain Choquet
Eric Van Den Neste
Brian Hill
Catherine Thieblemont
Federica Cavallo
Fatima De la Cruz
John Kuruvilla
Nada Hamad
Ulrich Jaeger
Paolo Caimi
Ronit Gurion
Krzysztof Warzocha
Sameer Bakhshi
Juan-Manuel Sancho
Michael Schuster
Miklos Egyed
Fritz Offner
Theodoros P. Vassilakopoulos
Priyanka Samal
Matthew Ku
Xiwen Ma
Kelly Corona
Kamal Chamoun
Jatin Shah
Sharon Shacham
Michael G. Kauffman
Miguel Canales
Journal of Hematology & Oncology, 14
[19] Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
Maerevoet, Marie
Zijlstra, Josee M.
Follows, George
Casasnovas, Rene-Olivier
Vermaat, J. S. P.
Kalakonda, Nagesh
Goy, Andre
Choquet, Sylvain
Van den Neste, Eric
Hill, Brian
Thieblemont, Catherine
Cavallo, Federica
De la Cruz, Fatima
Kuruvilla, John
Hamad, Nada
Jaeger, Ulrich
Caimi, Paolo
Gurion, Ronit
Warzocha, Krzysztof
Bakhshi, Sameer
Sancho, Juan-Manuel
Schuster, Michael
Egyed, Miklos
Offner, Fritz
Vassilakopoulos, Theodoros P.
Samal, Priyanka
Ku, Matthew
Ma, Xiwen
Corona, Kelly
Chamoun, Kamal
Shah, Jatin
Shacham, Sharon
Kauffman, Michael G.
Canales, Miguel
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
[20] Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data
Furqan, Fateeha
Hamadani, Mehdi
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13

← 1 2 3 4 5 →